Musculoskeletal and anti-inflammatory medications: a nursing reference

Musculoskeletal conditions — arthritis, gout, osteoporosis, inflammatory myopathies, muscle spasm — account for a large share of primary care, med-surg, and orthopedic nursing encounters. The medications used to manage them span multiple drug classes with very different mechanisms, monitoring requirements, and patient-teaching priorities. A nurse who cannot quickly distinguish a DMARD from a biologic, or recall why a bisphosphonate patient must stay upright for 30 minutes, is at a clinical disadvantage.

This reference consolidates the seven major drug categories used in musculoskeletal and inflammatory conditions into a single, exam-ready document. Each section delivers the mechanism, key agents, nursing considerations, patient education, and NCLEX-priority points you need for both clinical practice and the licensure exam. For broader pharmacology context, see the drug classifications nursing guide.

Quick reference table

NSAIDs — nonsteroidal anti-inflammatory drugs

NSAIDs are first-line agents for mild to moderate musculoskeletal pain and inflammation. They work by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, which reduces prostaglandin synthesis — the downstream mediator of pain, inflammation, and fever. COX-1 inhibition also reduces the protective prostaglandins that maintain the gastric mucosal barrier and support platelet aggregation, which is the source of the major GI and bleeding risks.

Key agents: ibuprofen (Advil, Motrin), naproxen (Aleve, Naprosyn), ketorolac (Toradol), celecoxib (Celebrex)

For patients managing joint pain related to osteoarthritis, NSAIDs are frequently the first medication prescribed before disease-specific therapy is considered.

How each agent differs

• Ibuprofen — shortest half-life (~2 hours); dosed every 4–6 hours; available OTC and prescription
• Naproxen — longer half-life (~12–17 hours); twice-daily dosing; favored for convenience
• Ketorolac — parenteral and oral; potent; limited to 5 days total due to cumulative GI and renal toxicity
• Celecoxib — COX-2 selective; spares COX-1 gastric protection; lower GI risk but similar renal and cardiovascular risk to non-selective NSAIDs; contraindicated in patients with sulfonamide allergy

Nursing considerations

• Always administer oral NSAIDs with food or milk to reduce gastric irritation
• Assess baseline renal function (BUN, creatinine) before starting; NSAIDs reduce renal prostaglandins and can precipitate acute kidney injury, particularly in patients who are dehydrated, elderly, or have pre-existing renal or heart failure
• Monitor for signs of GI bleeding: black or tarry stools, hematemesis, unexplained drop in hemoglobin
• Proton pump inhibitor (PPI) co-prescription should be considered for high-risk patients (age >65, prior GI ulcer, concurrent corticosteroid or anticoagulant use)
• NSAIDs inhibit platelet aggregation (except celecoxib) — hold before elective procedures
• Cardiovascular risk: all NSAIDs (including celecoxib) increase the risk of myocardial infarction and stroke with prolonged use; use the lowest effective dose for the shortest duration

Patient teaching

• Take with food or a full glass of water
• Report black or bloody stools, abdominal pain, swelling, or decreased urine output immediately
• Avoid concurrent use of multiple NSAIDs (including OTC ibuprofen)
• Alcohol increases GI bleeding risk

NCLEX high-yield

• Ketorolac maximum duration: 5 days (oral + parenteral combined)
• NSAIDs are contraindicated in the third trimester of pregnancy (premature closure of ductus arteriosus)
• Celecoxib is contraindicated with sulfonamide allergy
• NSAIDs + ACE inhibitors + diuretics = “triple whammy” — high risk of AKI

DMARDs — disease-modifying antirheumatic drugs

DMARDs slow or halt the structural joint damage that NSAIDs cannot. Unlike NSAIDs, which relieve symptoms without altering disease course, DMARDs target the underlying immune dysregulation driving inflammatory arthritis. The trade-off is that they have a slow onset — weeks to months — and carry significant toxicity profiles requiring ongoing monitoring. They are central to the management of rheumatoid arthritis.

Key agents: methotrexate (Rheumatrex), hydroxychloroquine (Plaquenil), sulfasalazine (Azulfidine), leflunomide (Arava)

Methotrexate

Methotrexate is the anchor DMARD for rheumatoid arthritis. It inhibits dihydrofolate reductase, suppressing rapidly dividing immune cells. It is given once weekly (not daily — a common dosing error with serious consequences).

• Monitoring: CBC, LFTs, creatinine at baseline and every 4–8 weeks during therapy
• Toxicity: hepatotoxicity, bone marrow suppression, pulmonary fibrosis (rare)
• Folic acid supplementation (1 mg daily) is prescribed concurrently to reduce mucosal and hematologic side effects
• Absolutely contraindicated in pregnancy (Category X — potent teratogen); women of childbearing age must use reliable contraception and avoid conception for at least 3 months after stopping
• Alcohol significantly increases hepatotoxicity risk — patients must abstain or severely limit intake

Hydroxychloroquine

Hydroxychloroquine (HCQ) is the mildest DMARD and is often first-line for mild RA or systemic lupus erythematosus. It modulates immune activation but does not require CBC monitoring.

• Key toxicity: retinopathy with long-term use — annual ophthalmologic screening is required after 5 years (or earlier in high-risk patients)
• Safe in pregnancy (one of the few DMARDs that is)
• Onset: 3–6 months

Sulfasalazine

Sulfasalazine is split by gut bacteria into sulfapyridine (anti-inflammatory) and 5-aminosalicylate. Used for RA and inflammatory bowel disease-associated arthritis.

• Monitoring: CBC every 2–4 weeks for the first 3 months, then every 3 months
• Contraindicated in sulfonamide or salicylate allergy
• May cause orange-yellow discoloration of urine and skin (benign)

Leflunomide

Leflunomide inhibits pyrimidine synthesis, reducing lymphocyte proliferation. It has a very long half-life (active metabolite persists for up to 2 years due to enterohepatic recirculation).

• Monitoring: LFTs monthly for 6 months, then every 6–8 weeks; CBC regularly
• Contraindicated in pregnancy (Category X); cholestyramine washout is required before conception to eliminate the active metabolite
• Hepatotoxicity risk increases with concurrent methotrexate or alcohol

Nursing considerations across DMARDs

• Educate patients that symptom improvement takes weeks to months — adherence during this lag phase is critical
• All DMARDs suppress immune function to varying degrees — monitor for signs of infection (fever, chills, productive cough)
• Live vaccines are contraindicated during DMARD therapy
• Hold DMARDs prior to major surgery and restart per physician guidance postoperatively

Biologics — TNF inhibitors

Biologic DMARDs are engineered proteins that target specific components of the immune cascade. The most widely used class for musculoskeletal conditions is the tumor necrosis factor (TNF) inhibitors, which block TNF-alpha — a key inflammatory cytokine in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Key agents: etanercept (Enbrel), adalimumab (Humira)

These agents are typically added when conventional DMARDs (particularly methotrexate) provide insufficient response. They dramatically reduce joint inflammation and radiographic progression but carry a significant infection risk.

Nursing administration

• Etanercept: subcutaneous injection, once or twice weekly
• Adalimumab: subcutaneous injection, every 1–2 weeks depending on indication
• Rotate injection sites; allow prefilled syringes to reach room temperature before injection
• Do not shake the solution

Pre-initiation screening

Before starting any biologic, the following must be completed:

• Tuberculosis screening: TST (tuberculin skin test) or IGRA blood test. TNF inhibitors reactivate latent TB. If the test is positive, TB treatment must be completed before initiating the biologic.
• Hepatitis B surface antigen and antibody: TNF inhibitors can reactivate hepatitis B. Prophylactic antiviral therapy is initiated if the patient is a carrier.
• CBC and liver function tests: baseline values
• Live vaccine status: all recommended vaccines should be given before starting, as live vaccines are contraindicated once on therapy

Infection risk

• TNF inhibitors increase susceptibility to bacterial, fungal, and opportunistic infections
• Hold therapy during active infections; do not restart until the infection has fully resolved and antibiotic treatment is complete
• Teach patients to report fever, chills, persistent cough, or any signs of infection immediately
• Rare but serious: increased risk of lymphoma with long-term use

Corticosteroids — systemic use in musculoskeletal conditions

Systemic corticosteroids (prednisone, methylprednisolone) are the most potent anti-inflammatory agents available and are used across virtually every inflammatory musculoskeletal condition — RA flares, gout, polymyalgia rheumatica, vasculitis, and as bridging therapy while awaiting DMARD onset. Their utility is real, but so are their consequences with prolonged use. Understanding both is essential for safe nursing practice.

Mechanism

Corticosteroids bind to intracellular glucocorticoid receptors, suppressing the transcription of inflammatory cytokines and reducing the activity of immune cells (neutrophils, macrophages, lymphocytes). The result is rapid, broad anti-inflammatory and immunosuppressive effect — onset within hours.

Side effects of prolonged use

Adrenal suppression and taper requirements

Prolonged corticosteroid use suppresses the hypothalamic-pituitary-adrenal (HPA) axis. The adrenal glands atrophy from lack of stimulation and cannot rapidly resume cortisol production if the medication is abruptly withdrawn. Abrupt discontinuation after more than 1–2 weeks of therapy can precipitate adrenal crisis — a life-threatening emergency characterized by hypotension, tachycardia, weakness, nausea, and severe fatigue.

• Taper the dose gradually over days to weeks depending on duration and dose of therapy
• Teach patients never to stop prednisone on their own
• During periods of physiologic stress (illness, surgery), patients on chronic steroids may need stress dosing (increased dose) because their suppressed adrenals cannot mount the normal cortisol surge

Osteoporosis risk

Long-term corticosteroid use is a leading cause of secondary osteoporosis. All patients on chronic steroids (>3 months) should receive calcium (1,000–1,200 mg/day), vitamin D (600–800 IU/day), and a DEXA scan at baseline. Bisphosphonate therapy is often co-prescribed. See the osteoporosis nursing reference for full management details.

Patient teaching

• Take with food to reduce stomach upset
• Never stop abruptly — follow the taper schedule exactly
• Report signs of infection; the immune response is blunted, so symptoms may be subtle
• Monitor blood sugar daily if diabetic
• Carry a medical alert card or ID if on long-term therapy

Muscle relaxants

Muscle relaxants reduce skeletal muscle spasm or spasticity and are used for acute musculoskeletal injuries, low back pain, and neurological conditions such as multiple sclerosis or spinal cord injury. All agents in this class cause CNS depression to varying degrees, and fall risk is the nursing priority across the category.

Key agents: cyclobenzaprine (Flexeril), methocarbamol (Robaxin), baclofen (Lioresal), tizanidine (Zanaflex)

How each agent works

• Cyclobenzaprine — acts centrally in the brainstem; structurally similar to tricyclic antidepressants. Indicated for short-term use (2–3 weeks) for acute muscle spasm. Has anticholinergic side effects (dry mouth, urinary retention, constipation).
• Methocarbamol — central acting; mechanism not fully established. Used for acute musculoskeletal pain. May discolor urine to brown, black, or green (benign).
• Baclofen — GABA-B receptor agonist; acts at the spinal cord level. Used primarily for spasticity (MS, spinal cord injury). Abrupt discontinuation can cause hallucinations and seizures.
• Tizanidine — alpha-2 adrenergic agonist; reduces spasticity at the spinal cord. Significant hepatotoxicity risk; LFTs at baseline and periodically. Strong interaction with ciprofloxacin (contraindicated combination — dramatically increases tizanidine levels).

Nursing considerations

• Fall precautions are mandatory for all muscle relaxant patients; assess environment, provide bed alarms, keep call light within reach
• Advise patients to change positions slowly (orthostatic hypotension)
• Avoid concurrent alcohol or other CNS depressants (opioids, benzodiazepines, antihistamines)
• Use with extreme caution in patients over 65 — these drugs are on the Beers Criteria list for inappropriate use in older adults
• Avoid in severe hepatic impairment (most agents are hepatically metabolized)
• Baclofen taper: do not stop abruptly — risk of withdrawal seizures and hallucinations
• Tizanidine: monitor LFTs; hold if patient starts fluoroquinolone antibiotics (ciprofloxacin contraindicated)

Patient teaching

• Do not drive or operate heavy machinery while taking muscle relaxants
• Avoid alcohol during treatment
• Report excessive sedation, difficulty urinating, or yellowing of the skin or eyes (tizanidine)
• Do not stop baclofen suddenly

Gout medications

Gout is caused by hyperuricemia — elevated serum uric acid — which leads to monosodium urate crystal deposition in joints. Medication management has two distinct phases with different drug classes: acute flare management and long-term urate-lowering therapy. Using a urate-lowering drug during an active flare can paradoxically worsen symptoms. For the full clinical picture, see the gout nursing reference.

Acute flare: colchicine

Colchicine is the preferred first-line agent for acute gout attacks when NSAIDs are contraindicated. It inhibits microtubule polymerization, preventing neutrophil migration into the inflamed joint.

• Dose: low-dose regimen is preferred — 1.2 mg at onset, then 0.6 mg one hour later; continue 0.6 mg once or twice daily until flare resolves
• Contraindicated in severe renal failure (CrCl <10 mL/min) — colchicine accumulates and is highly toxic; use is generally avoided when CrCl <30 mL/min in combination with strong CYP3A4 or P-gp inhibitors
• GI toxicity is the most common side effect — nausea, vomiting, diarrhea; a signal to reduce dose
• Drug interactions: clarithromycin, cyclosporine, statins, and antifungals significantly increase colchicine levels and toxicity risk
• Does not lower serum uric acid; treats inflammation only

Long-term urate-lowering therapy: allopurinol and febuxostat

Urate-lowering therapy is indicated for patients with recurrent gout attacks (≥2/year), tophi, uric acid nephrolithiasis, or gout with renal impairment. Therapy is initiated after the acute flare has fully resolved — starting during a flare prolongs it.

Allopurinol (Zyloprim):

• Xanthine oxidase inhibitor — reduces uric acid synthesis
• Start at low dose (100 mg/day) and titrate upward to target serum uric acid <6 mg/dL
• Dose-adjust for renal impairment (CrCl-based dosing)
• Serious risk: allopurinol hypersensitivity syndrome (AHS) — rare but potentially fatal; presents as fever, rash (may progress to Stevens-Johnson syndrome), and organ failure. Higher risk in patients with HLA-B*5801 allele (more prevalent in Han Chinese, Korean, Thai populations); genetic screening recommended in these populations
• Prophylactic colchicine or low-dose NSAID for the first 3–6 months of allopurinol initiation to prevent mobilization flares

Febuxostat (Uloric):

• Also a xanthine oxidase inhibitor; does not require renal dose adjustment at standard doses
• FDA black box warning: increased risk of cardiovascular death compared to allopurinol in patients with established cardiovascular disease; use allopurinol first-line

Probenecid

Probenecid is a uricosuric agent — it increases renal excretion of uric acid rather than reducing its production.

• Contraindicated in patients with a history of uric acid kidney stones (increases urine uric acid load) or with CrCl <50 mL/min (insufficient renal function to achieve uricosuric effect)
• Encourage high fluid intake (2+ liters/day) to prevent urate crystal precipitation in the kidneys
• Multiple drug interactions: reduces excretion of penicillins, cephalosporins, methotrexate, NSAIDs

Nursing considerations for gout medications

• Teach patients that starting allopurinol during a flare will worsen symptoms — wait until the acute attack resolves
• Serum uric acid target: <6 mg/dL (some guidelines target <5 mg/dL in patients with tophi)
• Monitor uric acid levels 2–4 weeks after dose changes and periodically during maintenance
• Dietary counseling: limit purine-rich foods (organ meats, shellfish, red meat), alcohol (especially beer), and high-fructose corn syrup beverages
• Adequate hydration reduces the risk of uric acid nephrolithiasis

Bisphosphonates

Bisphosphonates are the cornerstone of pharmacologic osteoporosis management and are also used for Paget’s disease of bone, hypercalcemia of malignancy, and bone metastases. They work by binding to hydroxyapatite in bone and inhibiting osteoclast-mediated bone resorption — the net effect is increased bone mineral density and reduced fracture risk. For full osteoporosis management context, see the osteoporosis nursing reference and the fractures nursing reference.

Key agents: alendronate (Fosamax), risedronate (Actonel), zoledronic acid (Reclast)

How bisphosphonates differ by route

• Alendronate — oral tablet; daily (10 mg) or weekly (70 mg) dosing
• Risedronate — oral tablet; daily (5 mg), weekly (35 mg), or monthly (150 mg)
• Zoledronic acid — IV infusion; annual infusion (5 mg over at least 15 minutes); preferred when adherence with oral therapy is poor or oral administration is not feasible

The esophageal precaution protocol (oral bisphosphonates)

Oral bisphosphonates are highly caustic to the esophageal mucosa. Strict administration technique is non-negotiable:

1. Take the tablet first thing in the morning, on an empty stomach
2. Swallow with a full 8 oz (240 mL) glass of plain water only — no coffee, juice, mineral water, or other medications
3. Remain upright (sitting or standing) for at least 30 minutes (60 minutes for alendronate per some labeling guidance) — do not lie down
4. Do not eat or drink anything else for at least 30 minutes after taking the dose

Failure to follow this protocol risks esophageal ulceration, esophagitis, and esophageal stricture. Patients with esophageal disorders (achalasia, stricture, difficulty swallowing) or those who cannot remain upright should receive IV zoledronic acid instead.

Osteonecrosis of the jaw

Osteonecrosis of the jaw (ONJ) is a rare but serious complication — exposed bone in the jaw that does not heal. Risk is substantially higher with:

• IV bisphosphonates used for malignancy (higher doses, more frequent infusions)
• Concurrent dental procedures, especially extractions or implants
• Poor oral hygiene, ill-fitting dentures

Nursing actions:

• Complete all necessary dental work before initiating bisphosphonate therapy
• Counsel patients to maintain excellent oral hygiene and see a dentist regularly
• Teach patients to report jaw pain, swelling, or exposed bone in the mouth promptly
• Discuss planned dental procedures with the prescribing provider before proceeding

Atypical femoral fractures

Long-term bisphosphonate use (>3–5 years) is associated with atypical subtrochanteric femoral fractures — often preceded by thigh or groin pain (prodromal pain). Patients on long-term therapy should report new or persistent thigh pain. Drug holidays are sometimes considered after 3–5 years in lower-risk patients. Ironically, the same drugs used to prevent fractures can, after prolonged use, increase a specific fracture risk — making patient monitoring and reassessment essential. See the fractures nursing reference for further detail.

IV zoledronic acid: infusion nursing considerations

• Infuse over at least 15 minutes; do not infuse faster (renal toxicity risk)
• Assess renal function before each infusion (CrCl ≥35 mL/min required for the osteoporosis dose; more restrictive for malignancy indications)
• Ensure the patient is well hydrated before the infusion
• Acute phase reaction is common after the first infusion — fever, myalgia, arthralgia, fatigue within 24–72 hours; acetaminophen pre-medication can reduce severity
• Hypocalcemia risk: ensure vitamin D and calcium status are adequate before infusion; monitor calcium post-infusion

Patient teaching for bisphosphonates

• Full 8 oz of plain water, stay upright 30–60 minutes, no food or other medications for 30 minutes (oral forms)
• Take calcium and vitamin D supplements as directed (but not at the same time as the bisphosphonate — calcium impairs absorption)
• Report jaw pain, new thigh pain, or swallowing difficulty immediately
• Continue scheduled dental hygiene and inform the dentist about bisphosphonate use before any invasive procedure

NCLEX priority table

Related references

• Rheumatoid arthritis nursing — disease overview, pathophysiology, and nursing management
• Osteoarthritis nursing — conservative and pharmacologic management
• Gout nursing — full clinical management of gout
• Osteoporosis nursing — fracture risk assessment, DEXA interpretation, and treatment
• Fractures nursing — orthopedic nursing, compartment syndrome, cast care
• Drug classifications nursing — broad pharmacology reference

Clinical information in this article is based on current evidence and published nursing pharmacology references including Lehne’s Pharmacology for Nursing Care, American College of Rheumatology guidelines, and NIH MedlinePlus drug information. Always verify drug dosing and protocols against current institutional formularies and clinical guidelines.